UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________________ FORM 10-Q __________________________________________________________ (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ☒ EXCHANGE ACT OF 1934 For the quarterly period ended March 30, 2024 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ☐ EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-36214 _____ ...

Hologic, Inc. (NASDAQ:HOLX) Q2 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Ryan Simon - Vice President, Investor Relations Steve MacMillan - Chairman, President and Chief Executive Officer Essex Mitchell - Chief Operating Officer Karleen Oberton - Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Jack Meehan - Nephron Research Puneet Souda - Leerink Partners Casey Woodring - JPMorgan Andrew Brackmann - William Blair Andrew Cooper - Raymond James Opera ...

Exhibit 99.1 Hologic Announces Financial Results for Second Quarter of Fiscal 2024 – Revenue of $1,017.8 Million, GAAP Diluted EPS of $0.72, and Non-GAAP Diluted EPS of $1.03; Revenue and Non-GAAP Diluted EPS Exceeded Guidance – – Total Company Organic Revenue Growth Excluding COVID-19 of 4.9% in Constant Currency; Against a 21.9% Prior Year Period Comparable – – Company Raises Full-Year Revenue Midpoint in Constant Currency and Raises EPS Guidance on Strong Margins – MARLBOROUGH, Mass. (May 2, 2024) – Holo ...

Hologic Inc. (HOLX) is set to report second-quarter fiscal 2024 results on May 2, after the closing bell.Strong strategic expansion globally is gaining investors’ confidence in Hologic. The company has been undertaking significant efforts to enter new geographies as many of its best-in-class products command a leading share in the domestic market. The company holds a disproportionately low market share internationally, indicating significant untapped potential. In addition, the continued spree of strategic ...

Analysts on Wall Street project that Hologic (HOLX) will announce quarterly earnings of $0.97 per share in its forthcoming report, representing a decline of 8.5% year over year. Revenues are projected to reach $1 billion, declining 2.5% from the same quarter last year.Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Prior to a company's earnings release, i ...

Hologic (HOLX) ended the recent trading session at $75.36, demonstrating a -0.03% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily gain of 0.87%. Elsewhere, the Dow saw an upswing of 0.67%, while the tech-heavy Nasdaq appreciated by 1.11%.The the stock of medical device maker has risen by 0.16% in the past month, leading the Medical sector's loss of 6.67% and the S&P 500's loss of 3.97%.The investment community will be paying close attention to the earning ...

Hologic, Inc. (HOLX) GYN Surgical is expected to have registered vital contributions from MyoSure and the Related fluid system, with an increasing contribution from its laparoscopic portfolio.Moreover, Hologic’s Molecular Diagnostics business is likely to register strong growth driven by a combination of newer assays like BV and CV/TV.We anticipate HOLX’s second-quarter fiscal 2024 performance, scheduled for release on May 2 after the closing bell, to reflect these aspects.Click here to know how the company ...

Hologic (HOLX) closed the most recent trading day at $77.54, moving +0.27% from the previous trading session. The stock's change was more than the S&P 500's daily loss of 1.2%. At the same time, the Dow lost 0.65%, and the tech-heavy Nasdaq lost 1.79%.The the stock of medical device maker has risen by 1.87% in the past month, leading the Medical sector's loss of 6.57% and the S&P 500's loss of 0.85%.Investors will be eagerly watching for the performance of Hologic in its upcoming earnings disclosure. The co ...

Hologic’s (HOLX) progress in the domestic and international markets, strong pipeline of products and continued solid performance of the Molecular Diagnostics segment bolster our confidence. However, uncertainty related to COVID-19-related test sales and macroeconomic issues persists. The stock carries a Zacks Rank #3 (Hold) currently.Hologic’s Molecular Diagnostics business is registering strong growth, driven by a combination of newer assays like BV, CV/TV and contributions from Amgen and HSV, as well as s ...

In the latest market close, Hologic (HOLX) reached $77.38, with a -0.77% movement compared to the previous day. The stock's change was less than the S&P 500's daily loss of 0.04%. Meanwhile, the Dow experienced a drop of 0.03%, and the technology-dominated Nasdaq saw an increase of 0.03%.Heading into today, shares of the medical device maker had gained 1.21% over the past month, outpacing the Medical sector's loss of 0.6% and lagging the S&P 500's gain of 2.57% in that time.The upcoming earnings release of ...